Try our Advanced Search for more refined results

US Coverage

Law360 Authority | Deep News & Analysis

Global Coverage

Law360 Pulse | The Business of Law

Mealeys

MLex

February 21, 2014

IN RE: Intercept Pharmaceuticals, Inc. Securities Litigation

Track this case

Case Number:

1:14-cv-01123

Court:

New York Southern

Nature of Suit:

Securities/Commodities

Multi Party Litigation:

Class Action

Judge:

Naomi Reice Buchwald

Firms

Companies

Sectors & Industries:

View recent docket activity

Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.

Coverage

  1. May 06, 2016

    Intercept To Pay $55M To End Investors' Stock-Drop MDL

    Intercept Pharmaceuticals Inc. will fork over $55 million to resolve multidistrict litigation brought by investors accusing it of securities fraud by concealing a liver drug's side effects, according to a stipulation filed Thursday in New York federal court.

1 other articles on this case. View all »

Parties

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Direct access to case information and documents.
  • All significant new filings across U.S. federal district courts, updated hourly on business days.
  • Full-text searches on all patent complaints in federal courts.
  • No-fee downloads of the complaints and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

View the parties now

Already a subscriber? Click here to login